Arbutus Biopharma Corporation Common Stock (ABUS) Stock Price

ABUSStock

$5.07+38.15%52W

Market Cap$1.00B

P/E—

PEG Ratio—

Div yield—

Beta0.76

ABUS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)1.75%

Price vs S&P 500 (4W)14.74%

VGM Score69.41

Book Value / Share (Quarterly)$1.32

P/TBV (Annual)2.38x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-28.80%

Cash Flow / Share (Quarterly)$-0.17

Price vs S&P 500 (YTD)-7.42%

Net Profit Margin (TTM)83.95%

EPS (TTM)$0.82

10-Day Avg Trading Volume6.56M

EPS Excl Extra (TTM)$0.82

Revenue Growth (5Y)15.30%

EPS (Annual)$-0.17

ROI (Annual)-41.87%

Net Profit Margin (5Y Avg)-528.86%

Cash / Share (Quarterly)$0.48

P/E Basic Excl Extra (TTM)5.61x

Revenue Growth QoQ (YoY)10054.54%

ROA (Last FY)-35.41%

Revenue Growth TTM (YoY)2889.93%

EBITD / Share (TTM)$0.81

ROE (5Y Avg)-56.00%

Operating Margin (TTM)81.72%

Cash Flow / Share (Annual)$-0.21

P/B Ratio3.47x

P/B Ratio (Quarterly)3.41x

Net Income / Employee (Annual)$-1,763,200

EV / Revenue (TTM)4.60x

Net Interest Coverage (TTM)-26.93x

ROA (TTM)112.24%

EV / EBITDA (TTM)5.63x

EPS Incl Extra (Annual)$-0.17

Current Ratio (Annual)15.73x

Quick Ratio (Quarterly)53.92x

3-Month Avg Trading Volume2.47M

52-Week Price Return38.15%

P/E Incl Extra (TTM)5.61x

Revenue / Employee (TTM)$10,076,100

Tangible BV / Share (Quarterly)$1.12

P/S Ratio (Annual)64.03x

Asset Turnover (Annual)0.15x

52-Week High$5.45

Operating Margin (5Y Avg)-554.99%

EPS Excl Extra (Annual)$-0.17

CapEx CAGR (5Y)-20.96%

Tangible BV CAGR (5Y)23.90%

26-Week Price Return13.68%

Quick Ratio (Annual)15.47x

13-Week Price Return10.22%

Total Debt / Equity (Annual)0.04x

Current Ratio (Quarterly)54.26x

Enterprise Value$881.33M

Revenue / Share Growth (5Y)-4.20%

Asset Turnover (TTM)1.34x

Book Value / Share Growth (5Y)-18.95%

Revenue / Employee (Annual)$741,200

Pretax Margin (Annual)-237.88%

Cash / Share (Annual)$0.48

3-Month Return Std Dev42.46%

Net Income / Employee (TTM)$8,458,900

ROE (Last FY)-43.75%

Net Interest Coverage (Annual)-37.59x

EPS Basic Excl Extra (Annual)$-0.17

P/FCF (TTM)43.90x

Receivables Turnover (TTM)2.11x

Total Debt / Equity (Quarterly)0.01x

EPS Incl Extra (TTM)$0.82

Receivables Turnover (Annual)7.30x

ROI (TTM)125.70%

P/S Ratio (TTM)4.71x

Pretax Margin (5Y Avg)-526.58%

Revenue / Share (Annual)$0.07

Tangible BV / Share (Annual)$1.12

Forward P/E16.37x

Price vs S&P 500 (52W)19.59%

P/E Ratio (TTM)5.61x

Year-to-Date Return5.41%

5-Day Price Return-2.50%

EPS Normalized (Annual)$-0.17

ROA (5Y Avg)-42.36%

Net Profit Margin (Annual)-237.88%

Month-to-Date Return16.82%

Cash Flow / Share (TTM)$-0.46

EBITD / Share (Annual)$-0.20

Operating Margin (Annual)-270.96%

LT Debt / Equity (Annual)0.04x

ROI (5Y Avg)-54.10%

P/E Excl Extra (TTM)5.61x

LT Debt / Equity (Quarterly)0.01x

EPS Basic Excl Extra (TTM)$0.82

P/TBV (Quarterly)2.38x

P/B Ratio (Annual)12.08x

Pretax Margin (TTM)83.95%

Book Value / Share (Annual)$0.40

Price vs S&P 500 (13W)8.26%

Beta0.76x

P/FCF (Annual)27.41x

Revenue / Share (TTM)$0.98

ROE (TTM)129.32%

52-Week Low$3.50

vGradeC

gGradeA

mGradeB

vgmGradeB

ABUS Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 12, 2026	-$0.03	-$0.04	-54.78%(-$0.01)
Q1 2026	May 13, 2026	-$0.06	$1.19	+2270.56%(+$1.25)
Q4 2025	Mar 23, 2026	-$0.06	-$0.01	+75.05%(+$0.04)
Q3 2025	Nov 13, 2025	-$0.04	-$0.06	-34.96%(-$0.01)
Q2 2025	Aug 6, 2025	-$0.09	$0.01	+115.23%(+$0.10)

ABUS Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.22

4.25

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
ABUSArbutus Biopharma Corporation Common Stock	C	A	B	$5.07
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Arbutus Biopharma Corporation Common Stock

Arbutus Biopharma is a clinical-stage biopharmaceutical company developing combination therapies for hepatitis B aimed at achieving a functional cure. Key pipeline candidates include imdusiran (AB-729), an RNAi therapeutic, and AB-101, an oral PD-L1 inhibitor. The company leverages proprietary Lipid Nanoparticle (LNP) delivery technology to optimize therapeutic efficacy.